1044 related articles for article (PubMed ID: 10952840)
1. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
2. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
3. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
4. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators.
Lancet; 1999 Feb; 353(9151):429-38. PubMed ID: 9989712
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
[TBL] [Abstract][Full Text] [Related]
6. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
Cofrancesco E; Cortellaro M; Leonardi P; Corradi A; Ravasi F; Bertocchi F
Thromb Haemost; 1996 Mar; 75(3):407-11. PubMed ID: 8701398
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina.
Klootwijk P; Lenderink T; Meij S; Boersma H; Melkert R; Umans VA; Stibbe J; Müller EJ; Poortermans KJ; Deckers JW; Simoons ML
Eur Heart J; 1999 Aug; 20(15):1101-11. PubMed ID: 10413640
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators.
Circulation; 1997 Aug; 96(3):769-77. PubMed ID: 9264481
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement.
Cofrancesco E; Cortellaro M; Corradi A; Ravasi F; Bertocchi F
Thromb Haemost; 1998 Mar; 79(3):509-10. PubMed ID: 9531030
[TBL] [Abstract][Full Text] [Related]
10. Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
Oldgren J; Linder R; Grip L; Siegbahn A; Wallentin L
Eur Heart J; 1999 Nov; 20(22):1657-66. PubMed ID: 10543929
[TBL] [Abstract][Full Text] [Related]
11. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial.
Christersson C; Oldgren J; Bylock A; Siegbahn A; Wallentin L
Eur Heart J; 2007 Mar; 28(6):692-8. PubMed ID: 17314111
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia.
Leitner JM; Firbas C; Mayr FB; Reiter RA; Steinlechner B; Jilma B
Clin Pharmacol Ther; 2006 Jan; 79(1):23-34. PubMed ID: 16413239
[TBL] [Abstract][Full Text] [Related]
13. Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
Yusuf S
Am J Cardiol; 1999 Sep; 84(5A):20M-25M. PubMed ID: 10505539
[TBL] [Abstract][Full Text] [Related]
14. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
Ohyama T; Hori T; Moriike M; Asano T; Hayashi H; Iwade K; Hosoda S
Thromb Haemost; 1998 Feb; 79(2):423-30. PubMed ID: 9493602
[TBL] [Abstract][Full Text] [Related]
15. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
16. The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.
Linder R; Oldgren J; Egberg N; Grip L; Larson G; Siegbahn A; Wallentin L
Eur Heart J; 1999 Apr; 20(7):506-18. PubMed ID: 10365287
[TBL] [Abstract][Full Text] [Related]
17. Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.
Oldgren J; Siegbahn A; Grip L; Linder R; Thygesen K; Wallentin L
Thromb Haemost; 2004 Feb; 91(2):381-7. PubMed ID: 14961168
[TBL] [Abstract][Full Text] [Related]
18. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention.
Mehta SR; Eikelboom JW; Rupprecht HJ; Lewis BS; Natarajan MK; Yi C; Pogue J; Yusuf S
Eur Heart J; 2002 Jan; 23(2):117-23. PubMed ID: 11785993
[TBL] [Abstract][Full Text] [Related]
20. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ
Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
